Keymed Biosciences Inc. (HKG:2162)

Hong Kong · Delayed Price · Currency is HKD

57.50

+1.60 (2.86%)

Jun 18, 2026, 4:08 PM HKT

28.78% (1Y)

Market Cap	16.94B +51.0%
Revenue (ttm)	797.12M +67.3%
Net Income	-581.60M
EPS	-2.12
Shares Out	294.60M
PE Ratio	n/a
Forward PE	28.65
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,165,480
Open	55.90
Previous Close	55.90
Day's Range	55.50 - 58.70
52-Week Range	43.80 - 81.85
Beta	-0.15
Analysts	Strong Buy
Price Target	92.95 (+61.65%)
Earnings Date	Aug 24, 2026

About Keymed Biosciences

Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis; CMG901/AZD0901, an antibody drug conjugate for treatment of advanced solid tumors; CM512, a TSLP x IL-13 bispecific antibody in Phase I clinical study... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2016

Employees 1,625

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2162

Full Company Profile

Financial Performance

In 2025, Keymed Biosciences's revenue was 716.31 million, an increase of 67.31% compared to the previous year's 428.12 million. Losses were -522.64 million, 1.44% more than in 2024.

Financial numbers in CNY Financial Statements

Analyst Summary

According to 11 analysts, the average rating for 2162 stock is "Strong Buy." The 12-month stock price target is $92.95, which is an increase of 61.65% from the latest price.

Price Target

$92.95

(61.65% upside)

Analyst Consensus: Strong Buy

Stock Forecasts